Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Impact Of Different Ablation Approaches on Outcome In Coexistent Atrial Fibrillation and Flutter (APPROVAL)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Monzino Hospital, Milan, Italy
Ospedale dell'Angelo, Mestre, Venice, Italy
Catholic University, Italy
Univ Tor Vergata, Rome, Italy
Information provided by (Responsible Party):
Andrea Natale, Texas Cardiac Arrhythmia Research Foundation
ClinicalTrials.gov Identifier:
NCT01439386
First received: September 21, 2011
Last updated: July 31, 2014
Last verified: July 2014
  Purpose

This prospective, multi-center, single blinded study aims to compare the influence of two different catheter ablation strategies, on long-term ablation outcome in terms of AF recurrence and quality of life (QoL) in patients presenting with coexistent AF and AFL. The two strategies to be evaluated are 1) the ablation of paroxysmal atrial fibrillation (PAF) with or without flutter (AFL) ablation (AF ± AFL) versus 2) AFL ablation alone.


Condition Intervention Phase
Atrial Arrhythmia
Quality of Life
Procedure: Catheter ablation
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
Official Title: Impact Of Different Ablation Approaches on Outcome In Coexistent Atrial Fibrillation and Flutter

Resource links provided by NLM:


Further study details as provided by Texas Cardiac Arrhythmia Research Foundation:

Primary Outcome Measures:
  • Recurrence of atrial arrhythmia [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    Any episode of AF/AT longer than 30 sec will be considered as a recurrence. Episodes that occur during the first 3 months after the procedure (blanking period) will not be considered as recurrence.


Secondary Outcome Measures:
  • Change in QoL score from baseline [ Time Frame: 12 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 86
Study Start Date: September 2011
Estimated Study Completion Date: July 2016
Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: AF ablation with or without AFL ablation
Pulmonary vein antral isolation (PVAI)with or without cavo-tricuspid isthmus (CTI) ablation
Procedure: Catheter ablation
PVAI with or without CTI ablation
Active Comparator: AFL ablation only
Cavo-tricuspid isthmus ablation only
Procedure: Catheter ablation
CTI ablation only

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age: ≥ 18years
  2. Patients presenting with paroxysmal AF and typical AFL
  3. Ability to provide written, informed consent

Exclusion Criteria:

  1. Reversible causes of atrial arrhythmia such as hyperthyroidism, pneumonia, pulmonary embolism, sarcoidosis and excessive alcohol consumption
  2. Bleeding disorder
  3. Contra-indication to anti-coagulants
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01439386

Locations
United States, Texas
Texas Cardiac Arrhythmia Institute, St. David's Medical Center
Austin, Texas, United States, 78705
Sponsors and Collaborators
Texas Cardiac Arrhythmia Research Foundation
Monzino Hospital, Milan, Italy
Ospedale dell'Angelo, Mestre, Venice, Italy
Catholic University, Italy
Univ Tor Vergata, Rome, Italy
Investigators
Principal Investigator: Andrea Natale, MD Texas Cardiac Arrhythmia Research Foundation
  More Information

No publications provided by Texas Cardiac Arrhythmia Research Foundation

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Andrea Natale, Executive medical director, Texas Cardiac Arrhythmia Research Foundation
ClinicalTrials.gov Identifier: NCT01439386     History of Changes
Other Study ID Numbers: TCAI_APPROVAL
Study First Received: September 21, 2011
Last Updated: July 31, 2014
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Atrial Fibrillation
Atrial Flutter
Arrhythmias, Cardiac
Cardiovascular Diseases
Heart Diseases
Pathologic Processes

ClinicalTrials.gov processed this record on November 20, 2014